
Transcranial Magnetic Stimulation - a new circuit-based strategy to decrease relapse among patients with drug and alcohol use?





Colleen A. Hanlon, Ph.D.


Professor, Clinical Neuromodulation Laboratory Comprehensive Cancer Center Wake Forest University School of Medicine

Disclosures:

Research Funding was exclusively provided by grants from the National Institutes of Health.







Temptation of Adam,
Tintoretto,
1551

Everyday modern struggles between Cogni

Cognitive Control

Appetitive Drive ACTION










Frontal-Striatal Circuits: Arousal, Control, Action

Alexander, DeLong, Strick Ann. Rev. Neuro. 1986






Haber & Knutson, Neuropsychopharm., 2010



What Is TMS?



"TMS can be rigorous, reliable, and sham-controlled"

George MS. Sci Am. 2003;289:66-73.

rTMS FDA-approved for depression – being widely adopted

4 FDA approved devices, Medicare reimbursable, 500+ machines sold




Growing International enthusiasm (esp. Asia and South America)

Clinical protocol for
Depression:
10 Hz Left DLPFC,
3000 pulses/day (20 min)
5 days/week
6 weeks


Remission rate: 15-30% in double blinded phase, >30% in open label

Durability: 90% retention of response at 12 months




Faraday's law of inductance (August 29, 1831)

Physics of TMS



A time-varying current (di/dt) in a wire loop will induce a magnetic field

The magnetic field will induce an electromotive force in an adjacent conductor



$$\nabla \times \mathbf{E} = -\frac{\partial \mathbf{B}}{\partial t}$$

$$\mathcal{E} = -L\frac{di}{dt}$$


L = inductance




E = Electromotive force

L = inductance


Mechanism of Action: Electromagnetic Induction








Physics of TMS




TMS Principles 1: Stimulation Breadth & Depth

Predicted by Maxwell's equations




1 V/cm = 20 mm deep,approx. 20mm wide




0.5 cm

1.5 cm

2.0 cm



Principle 2: Transynaptic modulation





TMS ---> synaptic activity ~2cm under the coil

and monosynaptic striatal targets


(Strafella, George, Etkin, Daskalakis, Lisanby, Pascual-Leone)

Principle 3: Behavioral and Brain effects are <u>frequency dependent</u>












Principle 4: Signal propagation is dependent on structural integrity

Fiber tract integrity calculated between frontal pole and ROIS









B. Relationship between FA







Daniel Lench, PhD (UMN)



Our Goal: Develop a TMS Based Strategy to Decrease Cue-reactivity

Where? How Much? Who?



"Individual Variability"


INFORMED DESIGN

TMS principle

*Insight from Preclinical Studies

*Insight from Clinical Research

Principle: Transcranial Magnetic stimulation can modulate frontal-striatal circuits



TMS ---> synaptic activity ~2cm under the coil


and monosynaptic striatal targets

(Strafella, George, Etkin, Daskalakis, Lisanby, Pascual-Leone)

MPFC: Translationallypredicted target for attenuating drug-reward

TARGET IDENTIFICATION:


Preclinical optogenetics demonstrates causal role of MPFC in drug-taking behavior



TARGET IDENTIFICATION:

Functional MRI demonstrates MPFC is transdiagnostic "hot


spot" for drug cue-reactivity




Hanlon et al, Translational Psychiatry, 2018


TARGET IDENTIFICATION:

The site most likely to directly effect cuereactivity is the Frontal Pole (data from 156 individuals)






Electric Field Model (SimNIBS)




How Much?

Who?

Theta-burst popularized by Huang, Rothwell and colleagues 2005






IMPORTANT METHODS ISSUE: TMS effects are amplified when paired with/primed by a task

WHY SHOW CUES?

A PRIMED NEURAL CIRCUIT IS MORE PLASTIC THAN AN UNPRIMED CIRCUIT

Cue-exposure during TBS delivery

110% rMT (hand), cTBS 3600 pulses (120 s ON, 60 s OFF, 120s ON)






Hanlon et al 2017, Drug Alc. Dep.

FP/vMPFC Theta Burst Protocol

(designed based on brain-skull distance & total dose/ramp)




110% RMT, 3600 pulses

(2 trains: 1800pulses/train, 60s intertrain interval) Active sham, 80-110% 15s ramp, Magpro Cool Sham coil


ENGAGEMENT- Can cTBS decrease alcohol cue-associated vmPFC-striatal activity in alcohol users?

Blinded, sham controlled study;

N=24 heavy alcohol users



cTBS decreases
MPFC-Striatal and
MPFC- Insula Cuereactivity






Kearney-Ramos et al, BioPsych:CNNI 2018

CLINICAL TRIAL: Can cTBS decrease alcohol relapse (via attenuation of cue reactivity)?

10 day (active) sham-controlled cohort study: Treatment-Engaged Cocaine Users/Alcohol Users



CONSORT Diagram

Enrolled from 2015-2019


- ~200 MRI scans
- ~ 500 TMS sessions
- ~ 700 patient visits (14/patient)

Did not complete visits: 4

*1@ 9 sessions

* 2@ 7 sessions

* 1@ 6 sessions



cTBS increases 3 month Sobriety

Demographics	TOTAL	Sham TMS	Real TMS
Participants	50	25	25
Men/Women	32/18	16/9	16/9
Age	46	46.2 (12.1)	45.8 (11.5)
Race (HHS catagories)		19W, 5B, 1A	s 22W, 1B, 1Na
% Cigarette Smoker	58	52	. 64
BDI	18.9	17.3 (9.7)	20.5 (13.3)
STAI-Trait	47.9	47.3 (14.6)	48.5 (14.2)
AUDIT	25.8	26.0 (5.6)	25.6 (5.8)
Age First Use:	16.4	16.9 (6.8)	15.9 (7.7)
Duration of Use:	28.2	27.7	28.7



"Patients that received Sham TMS were nearly half as likely to be sober as those that received Real TMS"

IMPORTANT CLINICAL TRIAL STATS:

% Sober in last month Baseline 1 month 2 month 3 month





Individual Variability in Alcohol Cue Reactivity


The Data-Based Foundation (Group-Averaged Data)

The Computational Model

The Messy Reality for Each Individual










Average Alcohol Cue Reactivity (n=67) Severe Moderate AUD At Risk Drinkers

- Etoh > neutral cues
- thresholded at p=0.001, k>25.
- Strong activation in the PFC/ACC, visual cortex and striatum.







Individual Variability in Alcohol Cue Reactivity: Severe vs Moderate AUD vs At Risk Drinkers

The area of peak BOLD signal evoked by Alcohol versus Non-alcoholic beverage Cues

67 Individuals

AUDIT 20+ = Severe AUD AUDIT 15-19 = Moderate AUD AUDIT 8-14 = At Risk for AUD







Individual Variability in Alcohol Cue Reactivity

The area of peak BOLD signal evoked by Alcohol versus Non-alcoholic beverage Cues

67 Individuals







Individual Variability in Alcohol Cue Reactivity

The area of peak BOLD signal evoked by Alcohol versus Non-alcoholic beverage Cues

67 Indiviudals











Dan McCalley (Poster 8)

5, 15mm bilateral spherical ROIs. Center of spheres 1, 4 and 5 matches the center of mass from pre-existing AAL ROIs.

Center of 2 and 3 were defined manually along the same X coordinate (same position along the medial wall)



F(3,330)=2.114, p=0.079







Individual Variability in Alcohol Cue Reactivity: Men versus Women

The area of peak BOLD signal evoked by Alcohol versus Non-alcoholic beverage Cues


67 Individuals







Individual Variability – Baseline striatal activity influences TMS-related change

Measured aspects of neural architecture




cortical target (yellow)
and White Matter
integrity to subcortical
target (blue)





TMS for Cue-reactivity: Logical progression of development 2013-2019



Step 1: Which circuit should we choose?

TARGET IDENTIFICATION (2014, DAAD; 2016 Neuropsychopharm)

Step 2: Can we "reach" the frontal pole/vmPFC? (2015, Neuropsychopharm; 2017, Brain Stimulation)


Step 3: Can we modulate it in healthy individuals? (2015, PlosOne; 2018 BrainStim)

Step 4: Can we induce <u>transient</u> change in this circuit **TARGET ENGAGEMENT** (2017, DAAD; 2018, BioPsych:CNNI)

Step 5: Can we induce <u>sustainable LTP/LTD</u>in this circuit **TARGET CLINICAL TESTING** (unpublished, & in progress)

Step 6: Tailoring treatment to our patients - impulsive versus compulsive choice..... REFINING TARGET IDENTIFICATION

Will the best TMS stimulation site for AUD be dependent on the Stage of Addiction/ Symptom Profile/ Biotype?



Executive

Function

Incentive

Salience

Negative

Figure 5. Network architecture of the brain from incentive formation to behavioral execution. A. The

Adapted from Powers et al 2011 – Included as Figure 5 in Dunlop, Hanlon, Downar, 2016

Acknowledgements

MUSC team

Daniel McCalley (POSTER 8!!)

Logan Dowdle, Ph.D.*
Daniel Lench, Ph.D.*
Ingrid Contreras
Julia Impertore
Sarah Hamilton, PA
Tonisha Kearney Ramos, Ph.D.*





Mentors &

"Open Minded Skeptics"

Mark S. George, MD
Kathleen T. Brady, MD PhD
Raymond Anton, MD
Howard Becker, PhD
Truman Brown, PhD
Elliot Stein, PhD







R01DA036617 (Hanlon), R21 DA 0412244 (Hanlon), P50 AA010761 (Becker), T32 007474 (Woodward), K05 AA017435 (Anton)

Postdoc & Engineer WANTED!
Do you like Electricity? Can you code? Want to try humans?
Contact me! @brainstimgrl


chanlon@wakehealth.edu


Are we stimulating the vMPFC or the OFC?





Cytoarchitectural Difference in Motor vs Prefrontal





Motor Cortex = Agranular (no layer 4)

PFC = GranularCortex (dense layer 4,
DM Thalamus inputs)



Baseline Alcohol Cue Reactivity in Clinical Trial:

Relapsers (2 month

Abstainers

The area of peak BOLD signal evoked by Alcohol versus Non-alcoholic beverage Cues

67 Individuals

